Valencia Technologies

Valencia Technologies occupies a focused position in neuromodulation and urological medical devices, addressing urge urinary incontinence with an implantable tibial-nerve stimulation system. Its competitive distinction is product form factor and treatment workflow: eCoin is designed as a small subcutaneous implant placed near the ankle, delivered through a minimally invasive office or outpatient procedure, and operated without an external controller or charging routine. The company’s category profile spans biotechnology, health care, health diagnostics, and medical devices, while its stated focus remains narrower than broad digital-health or general neurotechnology businesses. The 2025 financing and CEO appointment indicated an effort to support commercialization, and the 2026 acquisition by Boston Scientific provides access to the acquirer’s regulatory, sales, and medical-device infrastructure. The acquisition is therefore the clearest indicator of Valencia’s market position: a specialized device company with a differentiated implantable therapy that attracted strategic interest from a large industry participant. Standalone market share, revenue, adoption, and competitor comparisons remain unavailable.

Valencia Technologies shows a long development arc from its 2011 founding to a strategic exit in 2026. It raised five identified rounds totaling $45.95 million, including financings of $2.66 million in 2014, $2.22 million in 2015, $1.92 million in 2017, $4.16 million in 2019, and $35 million in 2025. The 2025 round was the major inflection point, representing roughly three-quarters of identified cumulative funding and coinciding with James D. Surek’s appointment as CEO. That combination suggests a shift toward commercialization and scaling rather than early technical development alone. Valencia’s core product, eCoin, is an FDA-approved implantable tibial neurostimulator for urge urinary incontinence, giving the company a regulatory and product-development milestone beyond preclinical research. The next major inflection point came on Jan 12, 2026, when Boston Scientific announced its acquisition of Valencia; completion was reflected in 2026 activity. Because the company is now part of Boston Scientific, future growth is more likely to be measured through integration, distribution, and broader commercialization than through standalone fundraising.